Citation Impact
Citing Papers
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
2009
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
2018
Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)
2012
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Pancreatic cancer
2004 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
2014
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Pancreatic cancer
2020 Standout
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
2013
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial
2005
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
2010
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
2014
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
The resurgence of platinum-based cancer chemotherapy
2007 Standout
PD-1/PD-L1 and immunotherapy for pancreatic cancer
2017
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Pancreatic cancer
2016 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Hepatocellular carcinoma
2021 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Molecular mechanisms of cisplatin resistance
2011 Standout
Pancreatic Adenocarcinoma
2014 Standout
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma
2010
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancer
2014
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
2014
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
2013
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
2010 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
2011
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Oxidative Stress in Cancer
2020 Standout
Gastric cancer
2020 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Pancreatic Cancer
2010 Standout
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
2014
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
2008
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer
2011
Pancreatic cancer
2011 Standout
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma
2012
Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study
2002
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
2006
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
2002
Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
2009
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
2010
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma
2013
Works of Pascal Artru being referenced
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
2009
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
2013
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma
2008
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
2012
Bimonthly Leucovorin, Infusion 5-Fluorouracil, Hydroxyurea, and Irinotecan (FOLFIRI-2) for Pretreated Metastatic Colorectal Cancer
2003
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
2006
Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastricor gastroesophageal junction carcinoma
2004
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
2002
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
2009
Review of the current status of KRAS mutation testing in France in 2011: The Flash-KRAS study.
2012
Intensive Systemic Chemotherapy Combined With Surgery for Metastatic Colorectal Cancer: Results of a Phase II Study
2005
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment
2017
Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study
2007
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
2000
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.
2013
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
2017
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
2016
Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
2011
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer
2004
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
2001
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
2007